Introduction {#S1}
============

Improvised explosive devices (IEDs) have induced blast traumatic brain injuries (TBI) in approximately one-quarter of military personnel deployed to combat stations in Operations Enduring Freedom and Iraqi Freedom ([@B1]). In addition to the blast wave, blast events often involve a blunt-force component, placing individuals at risk for alterations in consciousness, disruptions in memory, and headaches from both mechanisms of the blast-TBI ([@B2], [@B3]). Following deployment these military personnel are at high risk for on-going neurological and psychological symptoms, including post-concussive disorder (PCD), post-traumatic stress disorder (PTSD), and depression ([@B4], [@B5]). Our understanding of a complete and precise mechanism of blast-related pathology is limited, resulting in an inability to determine military personnel at risk for these chronic disorders, and to inform interventions to mitigate these risks.

Clinical studies report differential gene expression following TBI; however, these studies do not include blast-TBI, and most use post-mortem, neuronal tissue samples obtained from severe TBI patients ([@B6]--[@B10]). Studies that use imaging techniques report cortical thinning in the left superior temporal and frontal gyri ([@B11]) and altered neurocircuitry ([@B12]) in military personnel with a history of blast-TBI and chronic symptoms. These current studies are limited because they could neither examine the biological processes that contributed to neuronal compromise nor did they determine the impact of other variables that may affect gene expression or morphology of the brain, including comorbid PTSD, depression, and chronic pain. These considerations are essential, as not-determining the impact of these complexities can result in an inability to determine what the consequences are from the blast itself ([@B13]). Although there are advantages of pre-clinical models of blast, there are also challenges in translating findings that include differential injury mechanisms in the laboratory, limiting application to clinical patients including military personnel ([@B14]).

Although pre-clinical models are not in agreement in the preferential models of blast-TBI, there is definitive evidence linking blast-TBIs to neuronal function changes ([@B15]). Blast-TBIs result in cerebral edema and vasospasm, which contribute to global acute neuronal compromise through an influx of immune cells and inflammatory processes ([@B16], [@B17]). Within 24 h of blast-TBI, an up-regulation of glial fibrillary acidic protein, vimentin, and complement component 1 is observed ([@B18]), as well as an activation of microglia ([@B19]), which are key to TBI recovery as they propagate inflammation to neighboring neurons, providing vital protection. In traditional TBI, microglia communicates with peripheral immune cells to modulate immune activities ([@B20]). Specifically, microglia interacts with peripheral immune cells, resulting in a gene-expression signature in the peripheral blood cells that may be informative of central recovery activities ([@B21]). This assertion has been recently supported in a pre-clinical study that reports similar micro-RNA changes in the cerebral spinal fluid and serum following a blast, suggesting that peripheral samples provide insights into neuronal changes following blast ([@B22]).

Therefore, we suggest that central neuronal recovery mechanisms may be detected in the periphery through whole blood samples obtained from military personnel with a history of blast-TBI who are seeking care for chronic symptoms. To further investigate this postulation, we enrolled military personnel with medically documented blast-TBI, as well as controls without TBI. Instruments and a clinical evaluation were undertaken to determine current symptoms of PCD, PTSD, depression, and sleep disturbance. Differentially expressed genes related to blast-TBI were obtained by comparing military personnel with blast-TBI to matched controls without TBI using a whole-genome approach that eliminates any biased selection of biological targets. We addressed the possible impact of PTSD, depression, and sleep disturbance on gene-expression through group matching, on diagnoses of sleep disturbance, and symptom severity of PTSD and depression. This approach may provide a minimally invasive opportunity to investigate the gene-expression pathways that contribute to blast-TBI pathology in military personnel. We expect this line of research to ultimately inform pharmacological agents to better treat military personnel with chronic symptoms and deficits following a blast-TBI.

Materials and Methods {#S2}
=====================

Clinical methods {#S2-1}
----------------

This study was an observational assessment of U.S. military personnel at the Madigan Army Medical Center who had been deployed within the previous 18 months. Exclusion criteria included (1) no history of drug or alcohol abuse in the previous year and (2) no current medical condition that required substantial treatments (cancer, diabetes, HIV, autoimmune disorders), or a severe psychiatric condition (i.e., schizophrenia or bipolar disorder). Subjects with neurological disorders other than headaches, e.g., multiple sclerosis, seizure disorders, and a history of stroke, were excluded. Subjects with blast-TBI were identified by having a blast-TBI documented in their medical record. Blast-TBI cases did not require a pre-specified severity of PCD symptoms. Controls neither have a medical history of any TBI in their records nor report a TBI when asked. Controls were matched to blast-cases as much as possible on critical variables that would have influenced gene-expression including the following: age, gender, race/ethnicity, and diagnoses of sleep disorder, and symptom severity of PTSD and depression. The medical record was used to determine the number and type of prescribed medications that military personnel were prescribed. This study was approved by the institutional review board at the Madigan Army Medical Center, and informed consent was obtained from each individual prior to any baseline measurements.

### Determination of TBI {#S2-1-1}

The case history of TBI was extracted from medical records of the 117 military personnel enrolled in a larger observational study. Clinical information obtained includes the following: type of injury, diagnosis of TBI that includes severity, loss of consciousness, and time since the TBI. To be a blast-TBI case, the participant must also have reported sustaining a TBI through administration of the warrior administered retrospective casualty assessment tool (WARCAT) ([@B23]). A negative response to the WARCAT was necessary to be in the control group. This tool obtains data on possible war-related TBI injuries and post-deployment injuries, and whether they were injured from mechanisms commonly associated with TBI while deployed, whether any injuries resulted in an altered mental status indicative of TBI, and/or whether specific somatic and neuropsychiatric symptoms commonly associated with mild TBI occurred after the injury (immediately post-injury and/or post-deployment). The somatic and neuropsychiatric symptoms were not used to make the diagnosis of TBI. The diagnosis of mild TBI was made in accordance with American Congress of Rehabilitation Medicine mild TBI criteria, which requires an injury event followed by a loss of consciousness or alteration of mental state and was consistent with criteria for TBI delineated by the Department of Defense and Department of Veterans Affairs.

### Determination of PCD, PTSD, and depression symptoms {#S2-1-2}

The neurobehavioral symptom inventory (NSI) was used to measure PCD symptom severity. The NSI is a 22-item measure designed to evaluate self-reported post-concussion symptoms (e.g., headache, balance, nausea, etc.). The NSI requires the test taker to rate the presence/severity of each symptom on a 5-point scale (none, mild, moderate, severe, very severe). A total score is obtained by summing the ratings for the 22 items (range = 0--88). The NSI has a high-internal consistency (total alpha = 0.95; subscale alpha = 0.88--0.92) and reliability (*r* = 0.88--0.93) ([@B24]). This instrument was administered to all participants.

Symptoms of PTSD were assessed by the PTSD checklist military version (PCL-M), resulting in a score between 0 and 80, with higher numbers indicating the greatest severity ([@B25]). The quick inventory of depressive symptomatology (QIDS) was used to measure total symptoms of depression, resulting in a score of 0--27 ([@B26]). Chronic pain was evaluated by the bodily pain score from the short form (36) health survey (SF-36). We used this in conjunction with the medical record to determine a diagnosis of pain, by either a score lower than 70 for military personnel with a pain diagnosis in their electronic medical record or a low-bodily pain subscale score (\<30) on the SF-36 ([@B27]).

Laboratory methods {#S2-2}
------------------

### RNA sample preparation {#S2-2-3}

Blood samples were collected in PAXgene blood RNA tubes and processed with PAXgene™ Blood RNA Kits (PreAnalytiX, Qiagen) for RNA extraction according to the manufacturer's instruction. Quality and quantity of extracted RNA were evaluated with the NanoDrop DN-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) and the Agilent Bioanalyzer 2100 eukaryotic total RNA Nano assay (Agilent Technologies, Inc., Santa Clara, CA, USA). The 260/280 ratio ranged 2.03--2.34 and the RNA integrity numbers (RIN) were \>7.0 in all samples.

### Microarray gene-expression profiling {#S2-2-4}

Purified RNAs (100 ng) were amplified, fluorescently labeled, and hybridized to Affymetrix GeneChip Human Gene U133 Plus 2.0 Arrays (Affymetrix, Inc., Santa Clara, CA, USA), which contain more than 54,000 probes representing thousands of specific gene coding regions. After thorough washing, the raw data were obtained by laser scanning imaging. All RNA preparation and transcriptome assays were undertaken in the NINR laboratory based on manufacturer's protocols.

### Data analysis {#S2-2-5}

Descriptive statistics for all demographic and clinical variables were calculated using SPSS Statistics (IBM SPSS Inc., Chicago, IL, USA) (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Comparisons were made between the groups using *t*-tests. *A priori p*-values \<0.05 were considered significant.

###### 

**Demographics and clinical characteristics for blast-TBI + PCD (*N* = 19) and control (*N* = 17) groups**.

  -------------------------------------------------------------------------------------------------
                                       TBI + PCD\     Control\       Significance
                                       (*N* = 19)     (*N* = 17)     
  ------------------------------------ -------------- -------------- ------------------------------
  Mean age in years (SD)               32.00 (9.04)   30.94 (7.48)   *F*~1,35~ = 0.14, *p* = 0.72

  Mean BMI (SD)                        29.30 (3.76)   31.65 (4.82)   *F*~1,35~ = 2.03, *p* = 0.16

  Gender, % (No)                                                     N/A

   Male                                100.0% (19)    100.0% (17)    

  Race, % (No)                                                       χ^2^ = 4.22, *p* = 0.52

   Caucasian                           73.8% (14)     58.8% (10)     

   Mixed                               15.8% (3)      11.8% (2)      

   All other                           10.4% (2)      19.4% (5)      

  Rank, % (No)                                                       χ^2^ = 0.97, *p* = 0.62

   Lower enlisted                      57.9% (11)     58.8% (10)     

   Senior NCO                          36.8% (7)      35.3% (6)      

   Officer                             5.2% (1)       5.9% (1)       

  Sleep diagnoses, % (No)                                            χ^2^ = 2.79, *p* = 0.43

   OSA                                 10.5% (2)      5.9% (1)       

   Insomnia                            31.6% (8)      23.5% (4)      

   OSA + insomnia                      31.5% (6)      58.8% (10)     

   None                                15.8% (3)      11.8% (2)      

  Depression severity (QIDS)           9.6 (5.1)      8.7 (4.8)      *F*~1,35~ = 2.42, *p* = 0.10

  PTSD severity (PCL-M)                32.05 (18.8)   29.90 (15.1)   *F*~1,35~ = 2.31, *p* = 0.14

  Prescribed medications, % yes (no)   36.8% (6)      41.2% (7)      χ^2^ = 1.51, *p* = 0.51

   SSRI                                15.8% (3)      11.8% (2)      

   Prazosin                            21.1% (4)      17.6% (3)      

   Anti-hypertensive                   15.8% (3)      23.5% (4)      
  -------------------------------------------------------------------------------------------------

*TBI, traumatic brain injury; PCD, post-concussive disorder; SD, standard deviation; no, number; NCO, non-commissioned officer; BMI, body-mass index; OSA, obstructive sleep apnea; QIDS, quick inventory of depressive symptomatology; PTSD, post-traumatic stress disorder; PCL-M, PTSD checklist military version; SSRI, selective serotonin reuptake inhibitor*.

###### 

**Neurobehavioral symptom inventory for blast-TBI + PCD (*N* = 19 and control (*N* = 17) groups**.

  --------------------------------------------------------------------------------------------
                          TBI + PCD\      Control\        Significance
                          (*N* = 19)      (*N* = 17)      
  ----------------------- --------------- --------------- ------------------------------------
  *Forgetfulness*         *3.19 (0.75)*   *1.71 (1.16)*   *F~1,35~*  = *18.72, p* \< *0.001*

  *Concentration*         *2.69 (0.70)*   *1.29 (1.16)*   *F~1,35~*  = *17.13, p* \< *0.001*

  *Slowed thinking*       *2.37 (0.89)*   *1.06 (1.30)*   *F~1,35~*  = *11.44, p* = *0.002*

  *Dizziness*             *1.19 (0.83)*   *0.41 (0.51)*   *F~1,35~*  = *10.56, p* = *0.003*

  *Headache*              *2.31 (1.08)*   *1.12 (1.05)*   *F~1,35~*  = *10.36, p* = *0.003*

  *Hearing problems*      *2.06 (1.18)*   *0.88 (1.22)*   *F~1,35~*  = *7.96, p* = *0.008*

  *Sleep difficulty*      *3.37 (0.72)*   *2.59 (0.87)*   *F~1,35~*  = *7.96, p* = *0.008*

  *Nausea*                *0.94 (1.06)*   *0.18 (0.39)*   *F~1,35~*  = *7.63, p* = *0.010*

  *Decision making*       *2.25 (1.07)*   *1.24 (1.15)*   *F~1,35~*  = *6.91, p* = *0.013*

  *Irritability*          *2.81 (0.66)*   *1.88 (1.32)*   *F~1,35~*  = *6.46, p* = *0.016*

  *Balance*               *1.19 (0.91)*   *0.53 (0.62)*   *F~1,35~*  = *5.93, p* = *0.021*

  *Numbness*              *2.06 (1.57)*   *0.82 (1.38)*   *F~1,35~*  = *5.82, p* = *0.022*

  *Coordination*          *1.38 (0.81)*   *0.65 (0.93)*   *F~1,35~*  = *5.73, p* = *0.023*

  *Frustration*           *2.44 (0.96)*   *1.53 (1.23)*   *F~1,35~*  = *5.52, p* = *0.025*

  *Light sensitivity*     *1.31 (1.08)*   *0.59 (0.87)*   *F~1,35~*  = *4.54, p* = *0.041*

  *Taste/smell changes*   *0.81 (0.98)*   *0.18 (0.73)*   *F~1,35~*  = *4.51, p* = *0.042*

  *Noise sensitivity*     *1.50 (1.21)*   *0.65 (1.12)*   *F~1,35~*  = *4.44, p* = *0.043*

  Vision problems         1.31 (1.14)     0.59 (0.94)     *F*~1,35~ = 3.99, *p* = 0.054

  Anxiety                 2.75 (1.24)     1.82 (1.51)     *F*~1,35~ = 3.69, *p* = 0.064

  Depression              2.00 (1.03)     1.35 (1.27)     *F*~1,35~ = 2.55, *p* = 0.120

  Appetite changes        1.56 (1.32)     0.88 (1.22)     *F*~1,35~ = 2.38, *p* = 0.133

  Fatigue                 2.75 (1.00)     2.47 (2.50)     *F*~1,35~ = 0.17, *p* = 0.680
  --------------------------------------------------------------------------------------------

*TBI, traumatic brain injury; PCD, post-concussive disorder*.

*Italic font: significant group difference. NSI scale ranges from 0 to 4 for each item, with a 0 indicating that the symptom is not present*.

Microarray data were analyzed for a total of 36 participants for gene-expression profiles using Partek Genomics Suite software (Partek Inc., St. Louis, MO, USA). The probe-level robust multichip average background correction, quantile normalization, log~2~ transformation, and probe-set summarization were performed on gene-expression intensity values. Multi-way analysis of variance (ANOVA) mixed models were constructed for differential expressions for both the blast-TBI + PCD (*N* = 19) and control (*N* = 17) groups. Since samples were processed on different dates, batch correction was applied. Pair-wise comparisons were made by setting the contrast between blast-TBI and control groups. Significant differentially expressed gene lists were generated based on criteria of 1.5 magnitude fold-change (up or down), and *p*-values corrected for false discovery rate (FDR \< 0.05) using the step-up Benjamini--Hochberg method.

Interactive pathway analysis (IPA) (Qiagen Ingenuity Systems, Redwood City, CA, USA) was performed on differentially expressed genes to identify gene interactions and networks associated with biological functions.

Clinical variables were compared using ANOVA models for continuous variables, and chi-square for categorical data. Although our data were small in sample size, it met the assumptions of the tests we used, including ANOVA. Bonferroni corrections were used to adjust for multiple comparisons.

Results {#S3}
=======

Demographic and clinical characteristics {#S3-3}
----------------------------------------

The demographic and clinical characteristics of the 36 participants used in this analysis are described in Table [1](#T1){ref-type="table"}. The blast-TBI group (*N* = 19) was group matched to a control group (*N* = 17) to ensure that the groups did not differ on any demographic \[age, body-mass index (BMI), gender, race, and military rank\] or clinical characteristics (depression, and PTSD symptom severity and sleep diagnoses). There was no difference in the total number of military personnel taking any prescribed medication, or the type of medications, the most common being serotonin reuptake inhibitors (SSRIs), anti-hypertensive, and prazosin. The mean ages of the blast-TBI and control groups were 32.0 and 30.9 years, respectively. The sample was male, primarily Caucasian, and demonstrated high rates of comorbid symptoms of sleep disorders, depression, and PTSD. The blast-TBI group reported a far greater severity of PCD symptoms compared to controls.

All 19 participants in the TBI group experienced a blast injury, and 84.25% had a loss of consciousness following the blast-TBI. By medical diagnosis in theater, approximately 78.95% had a mild blast-TBI, and 21.05% of the sample was diagnosed with a moderate blast-TBI. In this sample, a brain contusion was reported to have occurred at the time of the blast in 36.84% of the sample, and all were determined to be mild in severity. More than half of the sample had more than one blast-TBI (52.6%), and approximately one-third had (38.8%) three or more blast-TBIs. The time since TBI varied, with 3--6 months, 6--12 months, and more than 12 months having elapsed for 15.8, 31.6, and 52.7% of the group, respectively.

The breakdown of the 22 components of the NSI for both the blast group and control group are shown in Table [2](#T2){ref-type="table"}. Scores on 17 of the 22 components were significantly different between the two groups, based on a *p*-value of 0.05, and adjustment for multiple comparisons.

Differential gene expression in TBI {#S3-4}
-----------------------------------

Differential expression of transcripts between blast-TBI and control groups resulted in multiple down-regulated (Table [3](#T3){ref-type="table"}) and up-regulated genes (Table [4](#T4){ref-type="table"}). Notable down-regulated genes are membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase (*MARCH8*, −1.6123 fold-change), tensin-1 (*TNS1*, −2.368 fold-change), tripartite motif containing 58 (*TRIM58*, −1.918), Kruppel-like factor 1 (*KLF1*, −1.766), WNK lysine deficient protein kinase 1 (*WNK1*, −1.630), ankyrin1 (*ANK1*, −1.628), and epidermal growth factor receptor (*EGFR*, −1.526). Differentially expressed gene pathways are shown in the network figure (Figure [1](#F1){ref-type="fig"}), generated from the ingenuity knowledge database. Figure [1](#F1){ref-type="fig"} indicates that the majority of the genes relate to ubiquitin C (UBC), and that EGFR is related to multiple gene-networks.

###### 

**Significantly down-regulated genes comparing blast-TBI + PCD (*N* = 19) to control (*N* = 17) groups**.

  Probe-set ID   Gene symbol                            Gene title                                                                            *p*-Value   Fold-change
  -------------- -------------------------------------- ------------------------------------------------------------------------------------- ----------- -------------
  221748         TNS1                                   Tensin-1                                                                              0.00062     −2.3682
  215047         TRIM58                                 Tripartite motif containing 58                                                        0.00012     −1.9188
  210504         KLF1                                   Kruppel-like factor 1 (erythroid)                                                     0.00094     −1.7663
  221246         TNS1                                   Tensin-1                                                                              0.00061     −1.6963
  228770         GPR146///LOC100505551///LOC100505568   G protein-coupled receptor 146///uncharacterized LOC100505551///uncharacterized LOC   0.00029     −1.684
  221824         8-Mar                                  Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase                0.0001      −1.6534
  201912         GSPT1                                  G1 to S phase transition 1                                                            0.00057     −1.6369
  212430         RBM38                                  RNA binding motif protein 38                                                          0.00092     −1.6368
  1555068        WNK1                                   WNK lysine deficient protein kinase 1                                                 0.00017     −1.6307
  218863         TNS1                                   Tensin-1                                                                              0.00066     −1.6286
  205389         ANK1                                   Ankyrin 1, erythrocytic                                                               0.00088     −1.6284
  224690         FAM210B                                Family with sequence similarity 210, member B                                         0.00054     −1.6254
  224789         DCAF12                                 DDB1 and CUL4 associated factor 12                                                    0.00019     −1.618
  202242         TSPAN7                                 Tetraspanin 7                                                                         0.00015     −1.6131
  231933         March8                                 Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase                0.00065     −1.6123
  224693         FAM210B                                Family with sequence similarity 210, member B                                         0.0008      −1.6016
  227935         PCGF5                                  Polycomb group ring finger 5                                                          0.00077     −1.5973
  207801         RNF10                                  Ring finger protein 10                                                                0.00057     −1.5533
  217736         EIF2AK1                                Eukaryotic translation initiation factor 2-alpha kinase 1                             0.00035     −1.5522
  202974         MPP1                                   Membrane protein, palmitoylated 1, 55 kDa                                             0.00079     −1.5427
  221958         WLS                                    Wntless homolog (*Drosophila*)                                                        0.00085     −1.5417
  225167         FRMD4A                                 FERM domain containing 4A                                                             0.00037     −1.5352
  1565484        EGFR                                   Epidermal growth factor receptor                                                      8.01E-06    −1.5261
  201285         MKRN1                                  Makorin ring finger protein 1                                                         0.00033     −1.5139
  225168         FRMD4A                                 FERM domain containing 4A                                                             0.00065     −1.5086
  1565483        EGFR                                   Epidermal growth factor receptor                                                      4.11E-07    −1.5053
  235993         PSMF1                                  Proteasome (prosome, macropain) inhibitor subunit 1 (PI31)                            0.00026     −1.505

*Microarray differentially expressed genes between groups that passed FDR (5%)*.

*TBI, traumatic brain injury; FDR, false discovery rate*.

###### 

**Significantly up-regulated genes comparing blast-TBI + PCD (*N* = 19) to control (*N* = 17) groups**.

  Probe-set ID   Gene symbol   Gene title                                              *p*-Value   Fold-change
  -------------- ------------- ------------------------------------------------------- ----------- -------------
  242539         DIS3L2        DIS3 mitotic control homolog (*S. cerevisiae*)-like 2   0.000341    1.7507
  219787         ECT2          Epithelial cell transforming sequence 2 oncogene        0.000281    1.6386
  218883         MLF1IP        MLF1 interacting protein                                8.53E-05    1.6065
  1553696        ZNF569        Zinc finger protein 569                                 0.000737    1.5581
  228859         C4orf21       Chromosome 4 open reading frame 21                      0.000252    1.5335
  231909         ODF2L         Outer dense fiber of sperm tails 2-like                 0.000284    1.5258
  231899         ZC3H12C       Zinc finger CCCH-type containing 12C                    0.000174    1.5192
  219174         IFT74         Intraflagellar transport 74 homolog (*Chlamydomonas*)   0.000763    1.5179
  230165         SGOL2         Shugoshin-like 2 (*S. pombe*)                           1.47E-05    1.5107

*Microarray differentially expressed genes between groups that passed FDR (5%)*.

*TBI, traumatic brain injury; FDR, false discovery rate*.

![**Generated molecular network based on differential expression between traumatic brain injury (TBI) and control groups using ingenuity knowledge database**. Coloring is based on the expression values of the genes (fold changes shown), down-regulation in green and, up-regulation in red. Genes with no coloring are added from ingenuity knowledge database. Direct and indirect relationships are shown by solid and dashed lines, respectively. The arrow indicates specific directionality of interactions. Genes with an asterisk indicate that multiple identifiers (probe-sets) map to the gene in the molecular network.](fneur-05-00198-g001){#F1}

### Sub-group analyses {#S3-4-6}

We separated subjects with moderate TBI from mild, and also did a subsequent analysis on TBIs within the last 12 months compared to subjects with a TBI more than 12 months ago. Lastly, we grouped subjects by multiple blast-TBIs, compared to subjects with only one blast-TBI. None of these analyses yielded a significant finding over the 1.5-fold-threshold, with the adjustment for multiple comparisons.

Discussion {#S4}
==========

To our knowledge this is the first study to report differential gene expression in the peripheral blood of military personnel with a history of blast-TBI during deployment compared to matched controls. Here, we report that differential expression of genes involved in the secondary injury processes may contribute to the long-term symptoms of PCD that are common among this group. These findings are significant because the genes we report to be differentially expressed are related to neuronal recovery following TBI, suggesting for the first time that a peripheral sample of blood may be used to better understand central processes in a sample of military personnel who have chronic blast-TBI related symptoms.

Specifically, our finding of a reduction in the membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase (*MARCH8*) as well as tripartite motif containing 58 (TRIM58) in military personnel with blast-TBI suggest that adequate functionality of the ubiquitin proteasome is essential for recovery from blast-TBI. Protein ubiquitination protects neurons from the detrimental impact of accumulating reactive oxygen, nitrogen species, and free release of zinc initiates ([@B28]) by initiating the removal of oxidized or misfolded proteins that result following injury ([@B18]). In fact, higher concentrations of the protein encoded by UBC-terminal hydrolase-L1 is one of the primary proteomic biomarkers of acute TBI ([@B29]--[@B31]), with high concentrations being related to the onset of chronic symptoms in pediatric patients ([@B30]).

Pre-clinical models link blast-TBIs to the activation of the autonomous nervous system and the neuroendocrine--immune system, suggesting that neuronal pathology results from the over-activation of multiple biological systems ([@B32]). For example, blast-TBIs result in increases in inflammatory cytokines and chemokines, as well as orexin A, and neuropilin-2 release ([@B33]). Pre-clinical models also link blast to an increase in UCH-L1 in blood and CSF, with CSF elevations lasting for 14 days, as well as increases in other putative biomarkers of brain injury glial fibrillary acid protein, and neuron-specific enolase ([@B34]). Minimization of the ubiquitin pathway following a blast-TBI, by inducing hypothermic conditions, resulted in less UCH-L1 activity following blunt force and a reduction of neuronal and glial damage ([@B35]). Therefore, additional studies are needed to determine how the ubiquitin pathway relates to neuronal damage following blast, and if it may be a pharmacological target to promote neuronal recovery from blast.

Therefore, reduction in the expression of this gene suggests that this process is down-regulated and may contribute to chronic neurological symptoms and impairments in military personnel with a blast-TBI. This assertion is further supported by pre-clinical models that link down-regulation in protein ubiquitination genes to poor neuronal repair ([@B36]), greater neuronal loss ([@B37], [@B38]), and less neurodegeneration ([@B39]). A previous study has linked increased zinc accumulations to reduced function of the ubiquitin pathway in cultured neurons ([@B40]). Additional studies that include acute biomarkers and determine changes in gene-expression over time are needed to determine the role of protein ubiquitination in blast-TBI recovery, as this line of research may inform pharmacological agents to promote recovery.

We also report reduced expression of TNS1, a gene that is pivotal to neuronal recovery following a TBI, which works in coordination with protein ubiquitination genes. Thus, our finding of a reduction in TNS1 in conjunction with reductions in protein ubiquitination genes leads us to question if a down-regulation in these genes may compromise neuronal recovery following blast-TBI, resulting in chronic neurological symptoms and deficits. Increases in the activity of TNS1 are linked to a risk for the onset of cancer and allergy induced asthma ([@B41], [@B42]). In a recent study, TBIs have been associated with an increased risk for brain cancer ([@B43]), suggesting that this TNS1 activity may increase morbidity risks following TBI. Therefore, additional studies are needed to validate our finding and to determine how TNS1 may relate to blast-TBI and chronic neurological symptoms.

Axonal injury and degeneration, whether primary or secondary, contribute to the morbidity and mortality risks following TBI, which is shaped in part by the EGFR pathway through the activation of astrocytes. Astrocytes promote neuronal survival through potentiation of collateral synapses, migration of neuronal progenitor cells, and differentiation of glial progenitor cells following TBI ([@B44], [@B45]). EGFR is also a peripheral precursor for vascular endothelial growth factor (VEGF), which plays a role in angiogenesis and has been shown to be neuroprotective following TBI in pre-clinical models ([@B46]--[@B48]). Thus, EGFR is similar to protein ubiquitination, down-regulation, and may occur following blast-TBI, and place military personnel at greater risk for poor neuronal repair and insufficient regeneration, resulting in the development of chronic symptoms and deficits. Future studies that utilize biomarkers collected sooner following the blast-TBI in larger and more representative samples may determine this relationship.

Although many of the genes that were significantly different in the blast-TBI group compared to controls related to neuronal compromise, a number of genes were not. One such gene was up-regulation of MLF1 interacting protein, a gene that suppresses cancer cell progression ([@B49]), as well the gene for outer dense fiber of sperm tails 2-like (ODF2L), which relates to defective spermatozoa ([@B50]). In addition, we also did not observe alterations in genes linked to blast-TBI in pre-clinical models, including inflammation ([@B33]), and putative biomarkers of brain injury, including glial fibrillary acid protein and neuron-specific enolase ([@B34]). It may be that since many participants in our sample population had a TBI that occurred over a year prior to enrollment, other non-related processes may have occurred, possibly contributing to the identification of non-expected candidates.

Our findings are limited by the cross-sectional nature of the study in a relatively small sample of military personnel. Additional larger studies are required to confirm our findings. Additionally, our design did not allow for randomization. To combat this limitation, we matched controls to blast-TBI participants on diagnoses of sleep disturbance and symptom severity of PTSD and depression. Although this allowed for isolation of gene expression changes more related to blast-TBI, the heterogeneity of symptoms of PCD and times since the blast event were issues that we were not able to address with the current design. In addition, without a third comparison group with a TBI not related to blast, we are unable to be certain that our findings are related to blast-TBI. We were limited in not including a clinician administered diagnostic tool to determine diagnoses of PTSD and depression, which is an issue in this group of patients who often present with complex symptoms that may be psychosomatic in nature. We report high rates of comorbidity in PCD, PTSD, and depression symptoms, as well as perceived health declines ([@B51]), and greater psychosomatic illness severity ([@B52]). Future larger studies that allow for comparison of differing symptom profiles of PCD and other comorbid symptoms will provide insights into both the shared and unique gene-expression pathways that underlie complex clinical presentations following blast-TBI.

Taken together, the identification of down-regulation in protein ubiquitination and mediation of this pathway in gene expression, as well as down-regulation of EGFR and TNS1, suggest involvement of these gene-expression pathways in chronic TBI pathology. Both of these gene-pathways protect neurons from secondary injuries following TBI and are highly specific to neurons ([@B53], [@B54]), and suggest that secondary injury or repair cascades can be detected in a peripheral sample of blood from military personnel with blast-related injuries even when injuries are not acute. Future studies are necessary to determine how variation in these gene-expression pathways may contribute to the heterogeneity in recovery from blast-TBI, as well as how manipulation of these pathways through the administration of pharmacological agents may promote recovery.
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